Picture of Valneva SE logo

VLA — Valneva SE Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+5%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-5.32%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for VLA

Momentum investing with Valneva Se (EPA:VLA) background image

Momentum investing with Valneva Se (EPA:VLA)

Intriguing research into stock market price trends shows that investors behave strangely when a stock trades close to its 52-week high... Despite flying high, holders of the shares are more likely to sell out and snatch a profit than h...

Valneva Se (EPA:VLA): buy, sell or hold? background image

Valneva Se (EPA:VLA): buy, sell or hold?

Shares in Valneva Se (EPA:VLA) are currently trading close to a 52 week high, with the share price up by around 32.0% - to 4.08 - over the past week. On a one-month basis, the Valneva Se price has risen by 46.8%. For investors holding...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Valneva SE EPS forecast chart

Profile Summary

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Directors

Last Annual
December 31st, 2020
Last Interim
June 30th, 2021
Incorporated
March 24th, 1999
Public Since
June 28th, 2007
No. of Employees
700
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
99,762,616

VLA Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email